Gender disparities in pulmonary hypertension at a tertiary centre in Cameroon by Aminde, L N et al.
892       October 2017, Vol. 107, No. 10
RESEARCH
Pulmonary hypertension (PH) describes a group of disorders resulting 
from an increase in pulmonary vascular resistance, pulmonary blood 
flow, pulmonary venous pressure, or a combination of these.[1] PH 
is defined as an increase in mean pulmonary arterial pressure of 
≥25 mmHg at rest, assessed by right heart catheterisation (RHC). [2] 
Based on shared pathological and haemodynamic characteristics 
and therapeutic approaches, PH is currently classified into five 
subtypes, namely PH groups 1 - 5.[3] Epidemiological studies from 
Western countries suggest that the prevalence of PH among African 
Americans is higher than that among Caucasians,[4] while in a 
community-based echocardiographic cohort study in Armadale, 
Australia, a prevalence of 9.1% and high mortality were observed.[5] 
In sub-Saharan Africa (SSA) however, there is some evidence that, 
based on the high prevalence of risk factors such as hypertension and 
other endemic communicable diseases such as schistosomiasis and 
HIV infection, the prevalence of PH may be higher than in Western 
countries.[6] Moreover, it has been suggested that left heart disease is 
the most frequent cause of PH worldwide.[7,8]
PH is a disease with devastating effects on quality of life and 
life expectancy, and is a potent cause of heart failure (HF) in 
general.[7,9-12] Indeed, one autopsy study from South Africa identified 
PH as one of the commonest causes of death, accounting for 
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Background. Pulmonary hypertension (PH) is a potent cause of heart failure and has been little investigated in the African setting.
Objective. To investigate the effects of gender on the clinical presentation, echocardiographic features and outcomes of patients with PH 
in Douala, Cameroon.
Methods. A prospective cohort study was conducted from March 2012 to December 2013 as part of the Pan African Pulmonary Hypertension 
Cohort study. PH was diagnosed by echocardiography and defined as a right ventricular systolic pressure >35 mmHg in the absence of acute 
right heart failure. Patients were followed up for a maximum of 12 months for primary endpoint mortality.
Results. In total, 130 patients with PH were recruited; 71 (54.6%) were women. The median age was 59.2 years for men and 58.3 years for 
women (p=0.76). Active smoking and alcohol use were more frequent in men than women (both p<0.001), but women had greater exposure 
to indoor cooking fumes than men (p<0.001). Previous tuberculosis infection (11.3% v. 1.7%) and S3 gallop rhythm (30.9% v. 11.9%) were 
more common in women (both p<0.03). Women had a significantly higher mean systolic blood pressure (134 mmHg v. 125 mmHg; p=0.04) 
and pulse pressure (53.8 mmHg v. 44.9 mmHg; p=0.01) and a lower mean haemoglobin concentration (10.4 g/dL v. 12.4 g/dL; p<0.05) 
compared with men. Echocardiographic left ventricular (LV) systolic dysfunction was more frequent in men: mean LV ejection fraction 42.6% 
v. 51.5% (p=0.01) and mean fractional shortening 21.4% v. 28.6% (p=0.01). The overall mortality rate was 20.3%, and rates were similar in the 
two groups (Kaplan-Meier log rank 1.1; p=0.30).
Conclusions. Despite differences in baseline characteristics including cardiovascular risk factors, mortality rates on follow-up were similar 
in men and women in this study. However, these different baseline characteristics probably suggest differences in the pathogenesis of PH in 
men and women in our setting that need further investigation.
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31% of all cardiovascular deaths.[13] The Pan African Pulmonary 
Hypertension Cohort (PAPUCO) study was established to investigate 
the epidemiology, causes and natural history of PH in Africa.[14,15] 
While the epidemiology of PH in Africa remains largely unknown, 
it is important to highlight the fact that clinical features of PH are 
often subtle and nonspecific, especially in the early stages, and may 
mimic other diseases, so that PH remains undiagnosed. Risk factors, 
epidemiology, clinical characteristics and outcomes of HF have 
gender variations that have been described among Caucasians.[16-18] 
Recent data from the largest HF registry in SSA suggest that HF was 
more likely to have been caused by rheumatic heart disease in women 
and conventional modifiable cardiovascular risk factors in men, 
although outcomes appeared to be similar.[19] The PAPUCO study 
presents a broad picture of PH in Africa,[15] but country-specific data 
on gender differences in the characteristics and outcomes of PH in 
Africa are still lacking.
Objective
To investigate gender differences in clinical characteristics, 
echocardiographic findings and outcomes in a cohort of patients 
with PH in Douala, Cameroon.
Methods
Study design and setting
The PAPUCO study design has been described in great detail,[14] 
and was registered on ClinicalTrials.gov (NCT02265887). In short, 
PAPUCO was a prospective pan-African multicentre cohort study of 
patients newly diagnosed with PH involving 12 specialist centres in 
SSA including Cameroon. The registry adhered to the Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines for reporting observational outcomes.
Eligibility
Through convenient sampling, all adult patients (≥18 years of age) 
who presented to the PAPUCO centre in Douala, Cameroon, with 
newly diagnosed PH were invited to take part in the study.
Diagnosis of PH
Diagnosis of PH was based on echocardiographic measurement of 
the right ventricular systolic pressure (RVSP) in the absence of acute 
right HF, reflecting pulmonary artery systolic pressure in the absence 
of pulmonary artery stenosis. The RVSP was obtained by measuring 
the tricuspid regurgitant jet velocity via a pulsed Doppler study of the 
tricuspid valve. The gradient between right atrium (RA) and right 
ventricle (RV) was obtained using the simplified Bernoulli equation 
(4 × [tricuspid jet velocity]2). This value was then added to the RA 
pressure (fixed value from 5 to 20 mmHg estimated by measuring the 
inferior vena cava size and its change with spontaneous respiration 
during echocardiography) for RVSP. A value of >35 mmHg was 
considered PH. Details of the echocardiographic assessment have 
been described previously.[14]
Data collection and study procedures
Patients were interviewed and examined and data were entered on 
an electronic case report form.[14] General and clinical characteristics 
included age, sex and risk factors for cardiovascular disease (CVD). 
A family history of CVD was defined as a documented family history 
of CVD; hypertension as a systolic (diastolic) blood pressure of ≥140 
(90) mmHg, a documented history of hypertension or prescribed 
antihypertensive medication; presence of diabetes as a fasting blood 
glucose level of ≥7 mmol/L, a documented history of diabetes or 
prescribed blood sugar-lowering agents; smoking as never having 
smoked, being an ex-smoker (if the patient had smoked for at least 
3 years in the past, but had stopped at time of presentation) or being 
a current smoker (patients who smoked at least one cigarette per day 
at the time of presentation); and alcohol abuse as intake of either 
more than three (two for women) standard glasses of wine per day or 
more than ten (five for women) local beers (one local beer contains 
28 g of alcohol) per week. The presence of symptoms (dyspnoea, 
fatigue, cough, palpitation) and signs on physical examination 
(distended jugular vein, pedal oedema, ascites, S3 gallop, P2 sound) 
was ascertained. The 6-minute walk test was also performed and the 
distance covered recorded in patients who had no contraindications. 
Patients underwent 12-lead electrocardiography, and standard blood 
results were obtained.
Follow-up and outcome assessment
From the time of recruitment, patients were followed up for 
12 months. During the follow-up visit or interview, conducted either 
in person or via telephone calls, patients and their relatives were 
questioned about the number of hospitalisations since recruitment 
(if patients were alive); if they were dead, the time lapse from 
recruitment to death was recorded.
Data and statistical analysis
Data were analysed using the Statistical Package for the Social 
Sciences IBM statistical software version 20 for Windows (SPSS Inc., 
USA). Categorical variables were summarised using frequencies and 
proportions, while continuous variables were summarised using 
means and standard deviations or medians with 25th and 75th 
percentiles. Group comparisons used χ2 and Fisher’s exact (where 
applicable) tests for categorical variables and the independent-
samples t-test for continuous variables. The Kaplan-Meier estimator 
was used to assess the risk of death during follow-up, with group 
comparisons based on the log-rank test. The Cox proportional hazard 
model was used to further investigate the differential effect of gender 
on mortality. Statistical significance was set at p<0.05.
Ethical considerations
Approval was obtained from the Institutional Review Board of the 
Faculty of Health Sciences, University of Buea (ref. no. 2013/0080/
UB/FHS/IRB) and Douala General Hospital, Cameroon (ref. no. 
179 AR/MINSANTE/HGD/DM/12/12) as well as from the National 
Ethics Committee (ref. no. 2013/11/363/L/CNERSH/SP). The 
PAPUCO study was approved by the University of Cape Town’s 
Human Research Ethics Committee (ref. no. 241/2011). The study 
adhered to the Declaration of Helsinki and all participants provided 
informed written consent prior to participation.
Results
Sociodemographic characteristics, risk factor  
profile and clinical findings
During the study period, 1 855 patients underwent echocardiographic 
examination. Of these, 130 (7.0%) had an RVSP >35 mmHg and were 
included in the study. All were of black African descent, and 71 (54.6%) 
were women. Table 1 summarises the baseline sociodemographic 
characteristics, risk factor profile and clinical findings of the cohort 
on a gender-specific basis. The mean age of the patients was 59 years, 
with no difference between men and women (p=0.76). Men were 
more likely to be in the age group 55 - 64 years, while the majority 
of women were aged ≥75 years. Fig. 1 depicts the age distribution of 
the study population according to gender. Cardiovascular risk factors 
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were prevalent in our cohort, hypertension (55.9% v. 52.1%), diabetes 
(15.3% v. 14.1%) and hypercholesterolaemia (16.9% v. 14.1%) being 
similarly distributed between men and women. Alcohol abuse (44.1% 
v. 14.1%) and current or previous smoking (32.2% v. 11.2%) were 
significantly more common in men (both p<0.01), while exposure to 
indoor cooking fumes (36.6% v. 3.4%) and previous tuberculosis (TB) 
infection (11.3% v. 1.7%) were more common in women (both p<0.03). 
At presentation, similar proportions of men and women were in New 
York Heart Association (NYHA) classes III and IV (74.6% v. 70.4%), 
although S3 gallop (30.9% v. 11.9%; p=0.011) was more common in 
women. Mean systolic blood pressure (134 mmHg v. 125 mmHg; 
p=0.041) and mean pulse pressure (53.9 mmHg v. 44.9 mmHg; p=0.01) 
were also significantly higher in women than in men.
Electrocardiographic, laboratory and  
echocardiographic findings
Table 2 summarises electrocardiographic and laboratory findings 
at presentation. No gender-specific differences were identified on 
Table 1. Baseline sociodemographic characteristics, risk factor profile, and clinical findings of patients with pulmonary 
hypertension in Douala, Cameroon, 2014
Variables
Males
(N=59)
Females
(N=71)
Total
(N=130) p-value*
Age (yr), mean (SD) 59.2 (16.1) 58.3 (18.9) 58.7 (17.7) 0.760
Family history of cardiovascular disease, n (%) 29 (49.2) 37 (52.1) 66 (50.8) 0.724
Hypertension, n (%) 33 (55.9) 37 (52.1) 70 (53.8) 0.601
Diabetes, n (%) 9 (15.3) 10 (14.1) 19 (14.6) 0.503
Hypercholesterolaemia, n (%) 10 (16.9) 10 (14.1) 20 (15.4) 0.630
Deep-vein thrombosis, n (%) 3 (5.1) 2 (2.8) 5 (3.8) 0.655
Pulmonary embolism, n (%) 3 (5.1) 3 (4.2) 6 (4.6) 0.565
Chronic lung disease, n (%) 3 (5.1) 7 (9.9) 10 (7.7) 0.331
Exposure to indoor smoke, n (%) 2 (3.4) 26 (36.6) 28 (21.5) <0.001†
Smoking, n (%) <0.01†
Current 4 (6.8) 3 (4.2) 7 (5.4)
Former 15 (25.4) 5 (7.0) 20 (15.4)
Never 40 (67.8) 63 (88.7) 103 (79.2)
Alcohol abuse, n (%) 26 (44.1) 10 (14.1) 36 (27.7) <0.0001†
HIV-positive, n (%) 1 (1.7) 1 (1.4) 2 (1.5) 1
Previous TB infection, n (%) 1 (1.7) 8 (11.3) 9 (6.9) 0.031†
NYHA class, n (%) 0.932
I 1 (1.7) 2 (2.8) 3 (2.3)
II 14 (23.7) 19 (26.8) 33 (25.4)
III 25 (42.4) 27 (38.0) 52 (40.0)
IV 19 (32.2) 23 (32.4) 42 (32.3)
Systolic murmur, n (%) 23 (38.9) 26 (36.6) 49 (37.7) 0.718
Diastolic murmur, n (%) 1 (1.7) 2 (2.8) 3 (2.3) 1
S3 gallop, n (%) 7 (11.9) 22 (30.9) 29 (22.3) 0.011†
Loud pulmonic P2, n (%) 11 (18.6) 9 (12.7) 20 (15.4) 0.330
BMI (kg/m2), mean (SD) 24.9 (5.0) 25.6 (7.3) 25.3 (6.3) 0.599
Systolic BP (mmHg), mean (SD) 125.0 (23.1) 134.2 (28.6) 130.0 (26.5) 0.041†
Diastolic BP (mmHg), mean (SD) 80.1 (16.8) 80.3(15.0) 80.2 (15.8) 0.939
Pulse pressure (mmHg), mean (SD) 44.9 (14.6) 53.9 (22.4) 49.8 (19.7) 0.012†
Pulse at rest (bpm), mean (SD) 87.5 (17.8) 83.3 (20.4) 85.2 (19.2) 0.223
Pulse oximetry (%), mean (SD) 95.3 (4.3) 96.4 (2.6) 96.0 (3.3) 0.250
Respiratory rate (breaths/min), mean (SD) 26.9 (9.1) 25.4 (7.1) 26.1 (8.1) 0.318
6-minute walk distance (m), mean (SD) 266.0 (168.7) 250.7 (112.7) 258.3 (141.8) 0.699
SD = standard deviation; TB = tuberculosis; NYHA = New York Heart Association; BMI = body mass index; BP = blood pressure.
*p-values based on t-test, χ2 test or Fisher’s exact test, where appropriate.
†Significant at p<0.05.
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Fig. 1. Age distribution of patients with pulmonary hypertension according 
to gender in Douala, Cameroon, 2014.
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electrocardiography. The mean haemoglobin concentration was 
lower in women than in men (10.4 g/dL v. 12.4 g/dL; p=0.042), while 
apparent differences in other biological characteristics did not reach 
statistical significance.
Table 3 summarises the echocardiographic findings. Compared 
with women, men had significant left ventricular (LV) systolic 
dysfunction: mean LV end-systolic diameter 47.3 mm v. 38.6 mm, 
(p<0.01), mean LV ejection fraction 42.6 v. 51.5 (p=0.01), and mean 
fractional shortening 21.4 mm v. 28.6 mm (p=0.01). Overall the 
mean RVSP was 55.6 mmHg without gender difference. A borderline 
difference in the severity of mitral regurgitation was apparent 
between men and women (p=0.070).
Aetiology of pulmonary hypertension, severity  
grading and outcome
Table 4 summarises subgroup classification of PH, severity at 
presentation and outcome in a subset of patients. Overall, 78.5% 
(n=102) of the cohort had PH caused by left heart disease, which 
was similar in men and women (81.3% v. 76.0%; p>0.05). Chronic 
thromboembolic PH was the least observed cause of PH in this 
study population (one patient). The majority (76.9%) of patients had 
moderate or severe PH (RVSP ≥45 mmHg). No difference was found 
between men and women.
We recorded 29 deaths (20.3%) and 15 readmissions (11.5%) after 
a median follow-up of 60 days (interquartile range 30 - 150). The 
in-hospital mortality rate was 18.5%. Kaplan-Meier estimator (log 
rank 1.1; p=0.30) (Fig. 2) as well as age-adjusted Cox regression 
models did not show a significant difference in survival between men 
and women (hazard ratio 0.82 (95% confidence interval 0.38 - 1.74); 
p=0.601) (Table 5).
Discussion
In this prospective cohort of patients with PH from specialised 
centres in Douala, Cameroon, a number of gender-related differences 
were observed. At baseline, men had smoking as a modifiable 
risk factor for CVD, while women had greater exposure to indoor 
cooking fumes. Both presented at advanced stages of the disease, men 
seeming more affected. Anaemia was more common in women, while 
Table 2. Baseline electrocardiographic and laboratory characteristics of patients with pulmonary hypertension in Douala, 
Cameroon, 2014
Variables
Males
(N=59)
Females
(N=71)
Total
(N=130) p-value*
Electrocardiographic findings, n (%)
Atrial fibrillation 16 (27.1) 19 (26.8) 35 (26.9) 0.848
Normal sinus rhythm 15 (25.4) 22 (30.9) 37 (28.5) 0.320
AV block type I 8 (13.5) 9 (12.7) 17 (13.1) 1
AV block type III 1 (1.7) 2 (2.8) 3 (2.3) 1
Sinus tachycardia 21 (35.6) 16 (22.5) 37 (28.5) 0.231
RV hypertrophy 6 (10.2) 6 (8.4) 12 (9.2) 1
LV hypertrophy 13 (22.0) 11 (15.5) 24 (18.5) 0.645
Laboratory findings, mean (SD)
Haemoglobin (g/dL) 12.4 (2.3) 10.4 (2.0) 11.4 (2.2) 0.042†
Haematocrit (%) 37.0 (7.5) 33.7 (6.1) 35.9 (6.8) 0.220
Platelet count (109/L) 192.6 (84.4) 258.4 (255.8) 225.1 (191.2) 0.123
Sodium (mmol/L) 138.0 (9.7) 137.3 (5.1) 137.7 (7.9) 0.708
Potassium (mmol/L) 4.1 (0.9) 4.1 (0.8) 4.0 (0.8) 0.911
Urea (mmol/L) 7.5 (12.0) 11.1 (22.0) 9.9 (35.1) 0.416
Creatinine (µmol/L) 93.6 (160.6) 56.4 (63.2) 75.9 (124.9) 0.180
Total cholesterol (mmol/L) 2.4 (1.3) 4.1 (2.8) 3.3 (2.0) 0.181
HDL cholesterol (mmol/L) 0.5 (0.2) 0.6 (0.3) 0.5 (0.2) 0.667
LDL cholesterol (mmol/L) 1.7 (1.1) 1.4 (0.9) 1.6 (1.0) 0.590
Triglycerides (mmol/L) 1.2 (0.7) 1.1 (0.5) 1.2 (0.6) 0.779
Fasting blood glucose (mmol/L) 9.4 (9.4) 10.6 (7.8) 10 (8.3) 0.643
C-reactive protein (nmol/L) 4 647.6 (4 247.6) 3 695.2 (4 504.8) 4 133.3 (4 323.8) 0.601
AV = atrioventricular; RV = right ventricular; LV = left ventricular; SD = standard deviation; HDL = high-density lipoprotein; LDL = low-density lipoprotein.
*p-values based on t-test, χ2 test or Fisher’s exact test, where appropriate.
†Significant at p<0.05.
Fr
eq
ue
nc
y,
 %
Age group (years)  
25
20
15
10
5
0
18 - 24     25 - 34    35 - 44     45 - 54     55 - 64    65 - 74       ≥75
Males
Females
1.0
0.8
0.6
0.4
0.2
0
Cu
m
ul
at
iv
e 
su
rv
iv
al
0               50            100            150            200           250           300
          
 Survival time (days)
Males
Females
Log rank 1.1; p=0.30
Fig. 2. Kaplan-Meier survival plot for mortality up to 12 months (360 days) 
comparing genders in patients with pulmonary hypertension in Douala, 
Cameroon, 2014.
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echocardiographic LV systolic dysfunction was frequent in men. 
Left heart disease was the main cause of PH in the two groups, and 
survival rates were similar.
The overall mean age in our study was 58 years, which is 
two decades younger than in reports from most industrialised 
countries,[5] but close to the 53 years reported in a recent study 
from Nigeria.[12] Women in our study were older than men, which 
has also been reported among Caucasians.[20] The mean age was, 
however, higher than that reported from a Portuguese PH registry. [21] 
While relatively younger age appears to be a striking feature of our 
cohort of SSA patients with PH, it should be noted that it is also a 
common finding in patients with HF, with relatively young patients 
being affected (median age 55 years).[22] One likely explanation is the 
over-representation of group 2 PH caused by left heart disease in our 
cohort, whether as a result of left HF or valvular heart disease, which 
usually occurs at a younger age.
The most frequent risk factors/comorbidities in the overall cohort 
were hypertension, diabetes, alcohol abuse and smoking. Alcohol 
abuse and active smoking were more common among men. This 
is similar to findings from the Registry to Evaluate Early and 
Long-Term Pulmonary Arterial Hypertension Disease Management 
(REVEAL) registry on pulmonary arterial hypertension in the USA, 
Table 3. Baseline echocardiographic parameters of patients with pulmonary hypertension in Douala, Cameroon, 2014
Variables
Males
(N=59)
Females
(N=71)
Total
(N=130) p-value*
Echocardiographic measurement, mean (SD)
Left atrial size (mm) 47.4 (8.0) 46.9 (11.7) 47.1 (10.2) 0.701 
Left ventricular end-systolic diameter (mm) 47.3 (16.1 38.6 (14.5) 42.5 (15.8) <0.01† 
Left ventricular end-diastolic diameter (mm) 56.2 (14.8) 51.7 (12.9) 53.7 (13.9) 0.072 
Left ventricular ejection fraction (%) 42.6 (19.9) 51.5 (18.9) 47.4 (19.8) 0.01† 
Fractional shortening (mm) 21.4 (11.3) 28.6 (12.0) 22.8 (10.8) 0.01† 
Interventricular septal diastolic diameter (mm) 12.1 (2.9) 10.6 (2.6) 11.3 (2.8) <0.001† 
Interventricular septal systolic diameter (mm) 14.3 (3.6) 14.2 (4.7) 14.3 (4.2) 0.988 
Posterior wall diastolic diameter (mm) 12.1 (4.5) 10.7 (2.9) 11.3 (3.8) 0.030† 
Posterior wall systolic diameter (mm) 14.7 (4.0) 14.2 (3.3) 14.5 (3.6) 0.521 
RVSP (mmHg) 53.6 (14.9) 57.3 (16.5) 55.6 (15.8) 0.168 
TAPSE (mm) 18.1 (6.2) 19.3 (6.4) 18.7 (6.3) 0.541 
Cardiac chamber and valvular evaluations, n (%)
Right atrial dilatation 0.478
Mild 11 (18.6) 14 (19.7) 25 (19.2)
Moderate 33 (55.9) 33 (46.5) 66 (50.8)
Severe 8 (13.6) 16 (22.5) 24 (18.5)
Right ventricular dilatation  0.551 
Mild 18 (30.5) 21 (29.6) 39 (30.0)
Moderate 21 (35.6) 21 (29.6) 42 (32.3)
Severe 6 (10.2) 8 (11.3) 14 (10.8)
Mitral regurgitation 0.070
Mild 20 (33.8) 25 (35.2) 45 (34.6)
Moderate 19 (32.2) 12 (16.9) 31 (23.8)
Severe 0 4 (5.6) 4 (3.1)
Mitral stenosis 0.302
Mild 0 0 0
Moderate 1 (1.7) 2 (2.8) 3 (2.3)
Severe 1 (1.7) 5 (7.0) 6 (4.6)
Aortic regurgitation 0.389
Mild 13 (22.0) 12 (16.9) 25 (19.2)
Moderate 3 (5.1) 8 (11.3) 11 (8.5)
Severe 0 0 0
Aortic stenosis 0.651
Mild 0 0 0
Moderate 0 1 (1.4) 1 (0.8)
Severe 1 (1.7) 1 (1.4) 2 (1.5)
Tricuspid regurgitation 0.376
Mild 13 (22.0) 15 (25.4) 28 (21.5)
Moderate 39 (66.1) 39 (54.9) 78 (60.0)
Severe 6 (10.2) 15 (21.1) 21 (16.2)
SD = standard deviation; RVSP = right ventricular systolic pressure; TAPSE = tricuspid annular plane systolic excursion.
*p-values based on t-test, χ2 test or Fisher’s exact test, where appropriate.
†Significant at p<0.05.
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where hypertension was a frequent comorbidity.[23] Similarly, a 
cross-sectional survey in Tanzania recently highlighted the fact that 
women had a 50% lower odds of hypertension compared with men. 
The slight predominance of conventional modifiable risk factors for 
CVD among men in this cohort is similar to findings among patients 
with HF in Africa,[19] but is contrary to reports from the EuroHeart 
Failure Survey.[24] The finding of hypertension as the most frequent 
CVD risk factor in our cohort is unsurprising, as over three-quarters 
of the patients had group 2 PH caused by left heart disease, which 
in our setting is frequently hypertensive heart disease with a final 
progression to left HF.[22.25] Exposure to indoor cooking fumes, 
especially from burning wood, was significantly more frequent 
among women. It is common for women in Africa to cook over an 
open fireplace, particularly in rural settings. However, this is not the 
case in middle- and high-income countries. The contribution of this 
exposure to the occurrence, severity and outcome of PH in African 
women still needs to be explored, and group 3 PH, caused by chronic 
lung disease, more intensively investigated. However, this requires 
additional equipment such as high-resolution computed tomography 
and lung function testing. Among the risk factors for chronic lung 
disease, a history of previous TB infection was also significantly 
more common in women than in men in our cohort. Unfortunately, 
the relationship to HIV infection (with a higher incidence of TB in 
HIV-infected individuals) could not be investigated, because HIV 
testing is not performed as a standard test in cardiac patients in 
Cameroon. Also, women were generally more obese than men and, 
although obesity has been independently associated with PH, this 
finding could simply reflect the high prevalence of female obesity in 
our population.[26] The reasons for some of our findings are unclear, 
but it remains possible that exposure of women to PH risk factors in 
our setting may be more complex and multifactorial than that of men, 
owing to a combination of the above risk factors (chronic lung disease 
and HIV) in varying degrees.
The majority of our patients, particularly men, presented at 
advanced stage of the disease (NYHA III/IV). This is similar to 
reports from Nigeria,[12] Australia[5] and Portugal,[21] where most 
patients present with features of advanced HF. This late presentation 
is probably due to nonspecific symptoms of PH in the early stages, as 
well as limited availability of diagnostic tools. Anaemia was observed 
more often in women than in men. Similar observations were made 
in The sub-Saharan Africa Survey of Heart Failure (THESUS-HF) 
registry, probably related to menstruation.[19]
Atrial fibrillation, sinus tachycardia and LV hypertrophy were the 
main electrocardiographic abnormalities in our cohort. Although 
previous reports and clinical guidelines suggest that patients with 
PH have RV hypertrophy on electrocardiograms,[2,27] this was not 
the case in our cohort, probably owing to the high prevalence of 
hypertension, LV dysfunction leading to LV hypertrophy; this 
consequently increases the left atrial pressure and may predispose 
to arrhythmias such as atrial fibrillation.[22,25] Supraventricular 
Table 4. Pulmonary hypertension subgroup classification, severity grading and outcome of patients with PH in Douala,  
Cameroon, 2014
Variables
Males
(N=59)
Females
(N=71)
Total
(N=130) p-value*
Subgroup classification of PH, n (%) 0.828
PAH (group 1) 5 (8.5) 6 (8.4) 11 (8.4)
PHLHD (group 2) 48 (81.3) 54 (76.0) 102 (78.5)
PHLD (group 3) 3 (5.1) 4 (5.6) 7 (5.4)
CTEPH (group 4) 0 1 (1.4) 1 (0.8)
Multifactorial (group 5) 3 (5.1) 6 (8.4) 9 (6.9)
Severity grading of PH, n (%) 0.241
Mild PH (RVSP 36 - 44 mmHg) 17 (28.8) 13 (18.3) 30 (23.1)
Moderate PH (RVSP 45 - 59 mmHg) 27 (45.8) 32 (45.1) 59 (45.4)
Severe PH (RVSP ≥60 mmHg) 15 (25.4) 26 (36.6) 41 (31.5)
Outcome of PH
Overall mortality, n (%) 15 (25.4) 14 (19.7) 29 (20.3) 0.348
In-hospital mortality, n (%) 14 (23.7) 10 (14.1) 24 (18.5) 0.211
 Overall time from presentation to death (days),  
mean (SD, range) 78.0 (77.2, 10 - 270) 121.5 (91.7, 7 - 270) 99.0 (85.9,  7 - 270) 0.170
Overall time from presentation to death (days), median (IQR)† 30 (20 - 150) 90 (30 - 240) 60 (30 - 150) 0.303
Overall re-hospitalisation rate through 360 days, n (%) 6 (10.2) 9 (12.6) 15 (11.5) 0.670
All-cause 90-day mortality, n (%)† 10 (16.9) 7 (9.9) 17 (13.1) 0.122
All-cause 180-day mortality, n (%)† 14 (23.7) 10 (14.1) 24 (18.5) 0.901
All-cause 270-day mortality, n (%)† 15 (25.4) 14 (19.7) 29 (22.3) 0.303
All-cause 360-day mortality, n (%)† 15 (25.4) 14 (19.7) 29 (22.3) 0.303
PH = pulmonary hypertension; PAH = pulmonary arterial hypertension; PHLHD = pulmonary hypertension due to left heart disease; PHLD = pulmonary hypertension due to lung disease or 
hypoxia; CTEPH = chronic thromboembolic pulmonary hypertension; RVSP = right ventricular systolic pressure; IQR = interquartile range; SD = standard deviation.
*p-values based on t-test, χ2 test or Fisher’s exact test, where appropriate.
†Comparison using the Kaplan-Meier log-rank test.
Table 5. Age-adjusted Cox regression analysis of the influence 
of age and gender on mortality among patients with 
pulmonary hypertension in Douala, Cameroon, 2014
Variables
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age 0.98 (0.95 - 1.00) 0.061 0.98 (0.96 - 1.00) 0.081
Gender 0.72 (0.34 - 1.51) 0.383 0.82 (0.38 - 1.74) 0.601
HR = hazard ratio; CI = confidence interval.
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arrhythmias such as atrial fibrillation are, however, said to 
occur in advanced stages of PH and are associated with clinical 
deterioration,[28] which probably explains the high case fatality in 
our cohort. On echocardiography, men had significant LV systolic 
dysfunction compared with women. With hypertension generally 
being more prevalent in men, it is likely that the observed LV 
dysfunction in men was due to hypertensive heart disease (as the 
hypertrophy as seen on the electrocardiogram). In contrast is the 
observation of a lower mean systolic blood pressure in men, which 
could potentially reflect advanced LV dysfunction and HF. Mitral 
valve lesions (stenosis and regurgitation) were frequent among 
women, with aortic lesions being more common in men. This is 
fairly consistent with the high prevalence of rheumatic heart disease 
in SSA[29] and its previously reported predominance in female HF 
patients in the region.[19] Although no significant gender difference 
in survival was observed, the high mortality rate from PH in this 
setting is worrying. Doctors in the region should have a high index 
of suspicion, and screening tools need to be put in place.
Study limitations and strengths
This study had a number of limitations. First, echocardiography 
was the main diagnostic tool used for the diagnosis of PH, as 
opposed to gold-standard RHC. This limitation of our registry has 
been discussed previously[14] and has to do with the challenges of 
diagnosing PH in the resource-limited settings that are so common 
in SSA. Echocardiography is much more affordable and available, 
and poses almost no risk compared with the invasive procedure of 
RHC.[30] Furthermore, the diagnostic accuracy of echocardiography 
has been reported in a meta-analysis and it is now widely recognised 
as a screening tool for PH.[31] The study was also conducted in 
specialised referral cardiovascular centres, and we acknowledge that 
patients who could not afford these services could have been missed; 
interpretation and generalisability of our results are therefore limited, 
as they probably represent findings from the participating centres. 
The small sample size may also limit the generalisability of our 
observations and disparities between genders, especially in respect of 
mortality and hospitalisation.
Our study nevertheless has merit in that it is among the few studies 
that have attempted to explore gender differences in epidemiology, 
clinical characteristics and echocardiographic features of patients 
with PH in a resource-limited setting. The prospective design also 
gives strength to the results obtained, and as an echocardiographic 
study it can be compared with many other studies worldwide that 
have used the same diagnostic modality. Our findings are relevant 
for both clinicians and public health experts, as they provided data 
on baseline clinical characteristics of PH as well as on potential 
risk factors. Clinicians should increase their index of suspicion, and 
public health experts should plan for risk factor interventions and 
allocation of resources.
Conclusion
Gender differences in risk factors and comorbidities of patients with 
PH in Africa exist, with modifiable cardiovascular risk factors in men 
as opposed to valvular heart disease in women. Interventions for the 
control of PH in men should target cardiovascular risk factors such 
as hypertension, alcohol abuse and smoking, while those for women 
should be directed towards chronic lung disease and rheumatic heart 
disease, as well as hypertension. Mortality from PH in our cohort was 
high, and there is a need for larger multicentre studies to confirm our 
findings as well as to explore further gender-related differences in 
PH in Africa. The different baseline characteristics observed could 
potentially reveal different pathogeneses of PH in men and women 
in our setting, which need further investigation.
Acknowledgements. We are grateful to the patients who participated in this 
study, and the management and staff of the study centres for authorising 
and collaborating with it.
Author contributions. LNA, AD, FT, KS and APK conceived and designed 
the study; LNA, AD, JN, SM, XK, FK, BHMN and M-SD contributed to 
data acquisition; LNA and APK did statistical analysis and interpretation; 
LNA drafted the initial manuscript; and APK, AD, KS, KBN and FT 
critically revised the manuscript. All authors read and approved the final 
manuscript.
Funding. None.
Conflicts of interest. None.
1. Fang JC, DeMarco T, Givertz MM, et al. World Health Organization pulmonary hypertension group 
2: Pulmonary hypertension due to left heart disease in the adult – a summary statement from the 
Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J 
Heart Lung Transplant 2012;31(9):913-933. https://doi.org/10.1016/j.healun.2012.06.002
2. Galiè N, Hoeper MM, Humbert M, et al., Task Force for the Diagnosis and Treatment of Pulmonary 
Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society 
(ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines 
for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-1263. 
https://doi.org/10.1183/09031936.00139009
3. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. 
J Am Coll Cardiol 2013;62(25 Suppl):D34-D41. https://doi.org/10.1016/j.jacc.2013.10.029
4. Todd NW, Lavania S, Park MH, et al. Variable prevalence of pulmonary hypertension in patients 
with advanced interstitial pneumonia. J Heart Lung Transplant 2010;29(2):188-194. https://doi.
org/10.1016/j.healun.2009.07.025
5. Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: Prevalence and mortality in 
the Armadale echocardiography cohort. Heart 2012;98(24):1805-1811. https://doi.org/10.1136/
heartjnl-2012-301992
6. Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: A global 
perspective. Eur Heart J 2013;34(46):3538-3546. https://doi.org/10.1093/eurheartj/eht388
7. Dzudie A, Kengne AP, Thienemann F, Sliwa K. Predictors of hospitalisations for heart failure and 
mortality in patients with pulmonary hypertension associated with left heart disease: A systematic 
review. BMJ Open 2014;4(7):e004843. https://doi.org/10.1136/bmjopen-2014-004843
8. Mocumbi AO, Thienemann F, Sliwa K. A global perspective on the epidemiology of pulmonary 
hypertension. Can J Cardiol 2015;31(4):375-381. https://doi.org/10.1016/j.cjca.2015.01.030
9. Szwejkowski BR, Elder DHJ, Shearer F, et al. Pulmonary hypertension predicts all-cause mortality in 
patients with heart failure: A retrospective cohort study. Eur J Heart Fail 2012;14(2):162-167. https://
doi.org/10.1093/eurjhf/hfr159
10. Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension 
in left ventricular dysfunction. J Am Coll Cardiol 1997;29(1):153-159. https://doi.org/10.1016/S0735-
1097(96)00436-6
11. Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension 
in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol 
2009;53(13):1119-1126. https://doi.org/10.1016/j.jacc.2008.11.051
12. Karaye KM, Saidu H, Bala MS, Yahaya IA. Prevalence, clinical characteristics and outcome of 
pulmonary hypertension among admitted heart failure patients. Ann Afr Med 2013;12(4):197-204. 
https://doi.org/10.4103/1596-3519.122685
13. Steenekamp JH, Simson IW, Theron W. Cardiovascular causes of death at Tshepong Hospital in 1 year, 
1989 - 1990: A necropsy study. S Afr Med J 1992;81(3):142-146.
14. Thienemann F, Dzudie A, Mocumbi AO, et al. Rationale and design of the Pan African Pulmonary 
Hypertension Cohort (PAPUCO) study: Implementing a contemporary registry on pulmonary 
hypertension in Africa. BMJ Open 2014;4(10):e005950. https://doi.org/10.1136/bmjopen-2014-005950
15. Thienemann F, Dzudie A, Mocumbi AO, et al. The causes, treatment, and outcome of pulmonary 
hypertension in Africa: Insights from the Pan African Pulmonary Hypertension Cohort (PAPUCO) 
Registry. Int J Cardiol 2016;221:205-211. https://doi.org/10.1016/j.ijcard.2016.06.242
16. Smilde TDJ, Damman K, van der Harst P, et al. Differential associations between renal function and 
‘modifiable’ risk factors in patients with chronic heart failure. Clin Res Cardiol 2009;98(2):121-129. 
https://doi.org/10.1007/s00392-008-0732-z
17. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Sex differences with respect to clinical 
characteristics, treatment, and long-term outcomes in patients with heart failure. Int J Cardiol 
2011;150(3):338-339. https://doi.org/10.1016/j.ijcard.2011.03.042
18. Brandsaeter B, Atar D, Agewall S, Norwegian Heart Failure Registry. Gender differences among 
Norwegian patients with heart failure. Int J Cardiol 2011;146(3):354-358. https://doi.org/10.1016/j.
ijcard.2009.07.014
19. Ogah OS, Davison BA, Sliwa K, et al. Gender differences in clinical characteristics and outcome 
of acute heart failure in sub-Saharan Africa: Results of the THESUS-HF study. Clin Res Cardiol 
2015;104(6):481-490. https://doi.org/10.1007/s00392-015-0810-y
20. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary 
arterial hypertension. Eur Respir J 2007;30(1):104-109. https://doi.org/10.1183/09031936.00092306
21. Baptista R, Meireles J, Agapito A, et al. Pulmonary hypertension in Portugal: First data from a 
nationwide registry. Biomed Res Int 2013;2013:489574. https://doi.org/10.1155/2013/489574
22. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 
1006 Africans from 9 countries. Arch Intern Med 2012;172(18):1386-1394. https://doi.org/10.1001/
archinternmed.2012.3310
23. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial 
hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial 
Hypertension Disease Management (REVEAL). Circulation 2010;122(2):164-172. https://doi.
org/10.1161/CIRCULATIONAHA.109.898122
24. Nieminen MS, Harjola V-P, Hochadel M, et al. Gender related differences in patients presenting with 
acute heart failure: Results from EuroHeart Failure Survey II. Eur J Heart Fail 2008;10(2):140-148. 
https://doi.org/10.1016/j.ejheart.2007.12.012
899       October 2017, Vol. 107, No. 10
RESEARCH
25. Dzudie A, Kengne AP, Muna WFT, et al. Prevalence, awareness, treatment and control of hypertension 
in a self-selected sub-Saharan African urban population: A cross-sectional study. BMJ Open 2012;2(4). 
https://doi.org/10.1136/bmjopen-2012-001217
26. Mandengue SH, Bita Fouda AA, Epacka Ewane M, Moumbe Tamba S, Kollo B. Epidemiology of 
obesity among students in Douala, Cameroon. Med Sante Trop 2015;25(4):386-391. https://doi.
org/10.1684/mst.2015.0523
27. Nauser TD, Stites SW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician 
2001;63(9):1789-1798.
28. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular 
tachyarrhythmias in pulmonary hypertension. Am Heart J 2007;153(1):127-132. https://doi.
org/10.1016/j.ahj.2006.09.008
29. Mayosi BM. The challenge of silent rheumatic heart disease. Lancet Glob Health 2014;2(12):e677-e678. 
http://dx.doi.org/10.1016/S2214-109X(14)70331-6
30. Khush KK, Tasissa G, Butler J, McGlothlin D, de Marco T, ESCAPE Investigators. Effect of pulmonary 
hypertension on clinical outcomes in advanced heart failure: Analysis of the Evaluation Study of 
Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. 
Am Heart J 2009;157(6):1026-1034. https://doi.org/10.1016/j.ahj.2009.02.022
31. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary 
hypertension: A systematic review and meta-analysis. Heart 2011;97(8):612-622. https://doi.
org/10.1016/j.ahj.2009.02.022
Accepted 6 April 2017.
